Nanna Therapeutics is a small-molecule focused therapeutics biotech subsidiary of Astellas, a Japanese global pharmaceutical company. Nanna and Mitobridge together comprise of the Mitobridge Division, a US- and UK-based research engine of Astellas reporting in to the Astellas Chief Scientific Officer, together we work as part of the Astellas Primary Focus Mitochondria area of research. Mitobridge is a Boston-based biotech acquired by Astellas in 2018, and Nanna Therapeutics, is a Cambridge, UK-based biotech, acquired in 2020. Further information can be found at www.nannatherapeutics.com.